Guidelines on the Use of International Nonproprietary Names (INNs) for Pharmaceutical Substances
(1997; 41 pages) Ver el documento en el formato PDF
Índice de contenido
Abrir esta carpeta y ver su contenido1. General introduction
Cerrar esta carpeta2. Elements in the INN system
Ver el documento2.1 Proposed INNs
Ver el documento2.2 Recommended INNs
Ver el documento2.3 Names for radicals and groups
Ver el documento2.4 Modified INNs (INNMs)
Ver el documento2.5 Cumulative list of INNs
Abrir esta carpeta y ver su contenido3. Principles for selection of INNs
Ver el documento4. Protection of INNs
Abrir esta carpeta y ver su contenido5. How to apply for an INN
Ver el documento6. References for supporting material
Ver el documentoAnnex 1: Background information on the INN programme
Ver el documentoAnnex 2: General principles for guidance in devising international nonproprietary names for pharmaceutical substances
Ver el documentoAnnex 3: List of common stems used in the selection of INNs
Ver el documentoAnnex 4: Specific groups of biological compounds
Ver el documentoAnnex 5: WHA46.19 - Nonproprietary names for pharmaceutical substances
Ver el documentoAnnex 6: Procedure for the selection of international nonproprietary names for pharmaceutical substances
Ver el documentoAnnex 7: Applications for INNs through national authorities (addresses)
Ver el documentoAnnex 8: INN request form
 

2.1 Proposed INNs

The selection of a new INN relies on a strict procedure. Upon receipt of an INN request form, the WHO Secretariat examines the suggested names for conformity with the general rules, for similarities with published INNs and potential conflicts with existing names, including published INNs and trademarks. A note summarizing the result of these checks is added and the request is subsequently forwarded to the INN experts for comments. Once all experts agree upon one name, the applicant is informed of the selected name.

Newly selected, proposed INNs are then published in WHO Drug Information, which indicates a deadline for a 4-month objection period. This period is allowed for comments and/or objections to the published names to be raised. The reasons for any objection must be stated clearly and these will be evaluated by the experts for further action. Users are invited to refrain from using the proposed name until it becomes a recommended INN, in order to avoid confusion should the name be modified. Two lists of proposed INNs are published yearly. An example is set out below.

acidum iocanlidicum (123I)

 

iocanlidic (123I) acid

15-(p-[123I]iodophenyl)pentadecanoic acid
radiodiagnostic agent

acide iocanlidique (123I)

acide 15-(p-[123I]iodophényl)pentadécanoïque
produit a usage radiodiagnostique

ácido iocanlídico (123I)

ácido 15-(p-[123I]iodofenil)pentadecanoico
agente de radiodiagnóstico

 

C21H33123IO2

74855-17-7

 

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013